Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost
exclusively affecting the central area of the face and the eyes.
Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral
antibiotic drug may be beneficial in patients with rosacea, particularly in those with
papulopustular phenotype and positivity to Lactulose Breath Test (L-BT).
The objective of this study is twofold:
1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults
with moderate-to-severe papulopustular rosacea.
2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of
patients.